Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 17 - Drugs for dermatological disorders
Patents for A61P 17 - Drugs for dermatological disorders (106,455)
06/2003
06/11/2003CN1423645A 维他命d类似物 Vitamin d analogues
06/11/2003CN1423638A Ox (adi) azolyl-hydroxamic acids useful as procollagen C-proteinase inhibitors
06/11/2003CN1423627A 维生素d类似物 Vitamin d analogues
06/11/2003CN1423557A Intracorporeal medicaments for photodynamic treatment of disease
06/11/2003CN1423550A Cosmetic compositions containing chick pea extract and retinoids
06/11/2003CN1423549A Personal care articles comprising a hydrophilic conditioning agent exhibiting a defined leaching value
06/11/2003CN1423528A Nutritional modules
06/11/2003CN1422859A Reaction method of biological alkali, reaction product and use thereof
06/11/2003CN1422671A Medical paste film
06/11/2003CN1422650A Ointment for treating various skin diseases and preparation method thereof
06/11/2003CN1422645A Formula of traditional Chinese herb for treating burn and preparation method thereof
06/11/2003CN1422644A Skin-beauty capsule
06/11/2003CN1422631A Chinese medicine for treating face acne
06/11/2003CN1422630A Lamina ointment for quickly treating burn and preparation method thereof
06/11/2003CN1422623A Chinese medicine composite external for treating alopecia areata and its preparation method
06/11/2003CN1422612A Nano-grade medicine controlled-releasing technology and preparation and use for viformicoid preparation
06/11/2003CN1111055C Ichthyosis treating cream and its preparation
06/11/2003CN1111048C Combined medicine for curing alopecia areata
06/11/2003CN1111033C Psoriasis treating medicine
06/11/2003CN1111032C Alopecia treating medicine
06/11/2003CN1111031C Medicine for treating leukoderma
06/10/2003US6576762 Heteroaromatic substituted amides with antagonistic activity to neurokinin 1 receptors
06/10/2003US6576660 Methods and compositions for regulation of 5-α-reductase activity
06/10/2003US6576648 Compound with growth hormone releasing properties
06/10/2003US6576618 Cholesterol containing cationic liposome having gene encoding insulin like growth factor I
06/10/2003US6576613 Title inhibitors of urokinase
06/10/2003US6576608 Stimulating tyrosine phosphorylation of Flt4 tyrosine kinase receptor in Flt4-expressing cell
06/10/2003US6576439 Contacting protein of given sequence with a test compound and detecting modulating activity; drug screening; can use for treatment of inflammatory conditions
06/10/2003CA2413024A1 Antipyretic preparation containing xylitol
06/10/2003CA2204437C Novel compositions based on a synergistic combination of one or more vrd ligands and retinoids
06/10/2003CA2192354C Corticotropin releasing factor against antagonist
06/10/2003CA2191795C Antisense oligonucleotide modulation of raf gene expression
06/07/2003CA2412838A1 Filtering composition containing a dibenzoylmethane derived filter type and a 2-hydroxybenzophenone aminosubstituted derived filter type
06/06/2003CA2436943A1 Hydantoin compounds useful as anti-inflammatory agents
06/06/2003CA2413479A1 Kit for reducing aching
06/05/2003WO2003046580A1 Assay for screening candidate drugs for the treatment of inflammatory diseases
06/05/2003WO2003046008A1 Therapeutic use of antibodies and fragments thereof binding primate ifn-gamma
06/05/2003WO2003045974A2 Methods and compositions for derepression of iap-inhibited caspase
06/05/2003WO2003045972A1 17α-ALKYL-17β-OXY-ESTRATRIENES AND INTERMEDIATES FOR THE PRODUCTION THEREOF, AND USE OF SAID 17α-ALKYL-17β-OXY-ESTRATRIENES FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS
06/05/2003WO2003045967A1 Aryl fused azapolycyclic compounds
06/05/2003WO2003045951A1 Triazolo[4,3-a]pyrido[2,3-d]pyrimidin-5-one derivatives, compositions containing same, preparation method and use thereof
06/05/2003WO2003045944A1 Aromatic sulfone hydroxamic acids and their use as protease inhibitors
06/05/2003WO2003045938A1 Quinoline derivatives, process for preparing them and use for the treatment of diseases mediated by s-cd23
06/05/2003WO2003045926A1 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine
06/05/2003WO2003045922A1 Sulfone derivatives and their use in the treatment of autoimmune diseases and allergies
06/05/2003WO2003045917A2 Ccr-3 receptor antagonists vii
06/05/2003WO2003045893A1 Double esters
06/05/2003WO2003045435A1 Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs
06/05/2003WO2003045412A1 Mint extract and related pharmaceutical compositions
06/05/2003WO2003045399A2 Composition based on diosgenin ester for topical use
06/05/2003WO2003045391A1 Pharmaceutical formulations comprising an immune response modifier
06/05/2003WO2003045379A1 Hydrazonopyrazole derivatives and their use as therapeutics
06/05/2003WO2003045366A1 Treatment of wounds and compositions employed
06/05/2003WO2003045363A2 Treatment of th2 dominated immunological disease states with progesterone receptor antagonists
06/05/2003WO2003045362A2 Treatment of th1 dominated immunological disease states with non-endogenous gestagen compounds
06/05/2003WO2003045349A2 Itch-relieving cosmetic and dermatological preparations
06/05/2003WO2003045338A1 Compositions comprising phenyl-glycine derivatives
06/05/2003WO2003045333A2 Treatment of hyperproliferative diseases using active vitamin d analogues
06/05/2003WO2003045318A2 Manipulation of cytokine levels using cd83 gene products
06/05/2003WO2003045228A2 Methods for treating autoimmune disorders, and reagents related thereto
06/05/2003WO2002060864A9 Process of obtaining compositions of stable lutein and lutein derivatives
06/05/2003WO2002048124A3 Piperazine derivatives
06/05/2003US20030105165 Gap junctions and EDHF
06/05/2003US20030105151 Anticancer agents; antiinflammatory agents; autoimmune diseases; rheumatic diseases
06/05/2003US20030105150 Method of treating of demyelinating diseases or conditions
06/05/2003US20030105142 Amide derivatives useful as inhibitors of the production of cytokines
06/05/2003US20030105135 Adrenergic receptors; gastrointestinal disorders, dietetics, urogenital disorders, antidiabetic agents
06/05/2003US20030105123 For therapy of respiratory system disorders
06/05/2003US20030105090 For therapy of cancer, diabetes
06/05/2003US20030105069 Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
06/05/2003US20030105063 Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines
06/05/2003US20030105050 Disorders caused by overproduction of collagen fibres, for example, liver cirrhosis, kidney, liver and heart fibrosis, scleroderma, hypertrophic scars and keloids
06/05/2003US20030105031 Administering therapeutically effective amount of one or more flavonoids and carrier for therapy of reactive and inflammatory dermatoses
06/05/2003US20030105027 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
06/05/2003US20030104992 A cyclic polypeptides; immunosuppressive anti-inflammatory activity, inhibiting antigen-induced inflammatory cell infiltration
06/05/2003US20030104975 Useful for identification of compounds that induce or inhibit the recruitment of the p160 family cofactors, especially TIF-2 and/ or SRCs cofactors (Translation initiation factor-2 and steroid receptor cofactors)
06/05/2003US20030104974 Dual inhibitorsof PDE 7 and PDE 4
06/05/2003US20030104970 Modulating the growth state of an epithelial cell by ectopically contacting the epithelial cell, in vitro or in vivo, with hedgehog polypeptide or patched therapeutic to promote or inhibit of proliferation of epithelial cell
06/05/2003US20030104589 Tissue adhesive using synthetic crosslinking
06/05/2003US20030104579 Pluripotent stem cells; antitumor agents; antiproliferative agents; antiinflammatory agents; veterinary medicine; tissue engineering
06/05/2003US20030104570 Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest
06/05/2003US20030104500 Enzymatic assays for screening anti-cancer agents
06/05/2003US20030104478 Screening modulators of g-protein activity: for use in treatment of nervous system disorders
06/05/2003US20030104400 Nucleotide sequences coding polypeptide for use in the diagnosis, prevention and treatment of infammatory, immunol;ogical and nervous system disorders
06/05/2003US20030104377 Tenascin-C nucleic acid ligands
06/05/2003US20030104040 Balancing the molecular properties (van der Waals forces and dipole moments) of all the components against those of all the components plus the particular active agent.
06/05/2003US20030104021 High electrolyte content W/O emulsions for treating irritated/sensitive skins
06/05/2003US20030104020 Chitosan compositions
06/05/2003US20030104019 Swellable clay and a peptizing agent; treating enzymatic dermatitis; premoistened wipes and diapers.
06/05/2003US20030104016 Reducing inflammation by topically applying totarol or an ester of totarol
06/05/2003US20030103973 Method for reducing tumor growth with VEGF antagonists combined with radiation and chemotherapy
06/05/2003US20030103954 Comprises vitamin D3 for regulating cell differentiation and/or cell proliferation
06/05/2003US20030103953 Comprises vitamin D3 for controlling cell differentiation and/or cell proliferation
06/05/2003US20030103924 Mixture containing polymeric carrier
06/05/2003CA2468717A1 Aryl fused azapolycyclic compounds
06/05/2003CA2468402A1 Ccr-3 receptor antagonists vii
06/05/2003CA2468390A1 Treatment of wounds and compositions employed
06/05/2003CA2468256A1 Compositions comprising phenyl-glycine derivatives
06/05/2003CA2468184A1 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine
06/05/2003CA2468071A1 Triazolo[4,3-a]pyrido[2,3-d]pyrimidin-5-one derivatives, compositions containing same, preparation method and use thereof
1 ... 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 ... 1065